Sign in
Taking people in United StatesPhase 4

Seizure Prevention in Traumatic Brain Injury With Levetiracetam and Lacosamide

Key facts

Who runs it
Wake Forest University Health Sciences
Where
Winston-Salem, United StatesSee the site
Trial code
Status
Recruiting
Phase
Phase 4
People taking part
600 people, planned
Started
18 Apr 2025
Expected to end
Apr 2027
Type of study
Interventional, 2 groups
Treatments tested
  • levetiracetam
  • lacosamide
Record updated
24 April 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • 18 years and older
  • Diagnosis of traumatic brain injury: severe, moderate, or mild with high-risk imaging features
  • Seizure prophylaxis with one of the two study drugs within 24 hours of initial injury
  • Patients admitted into the trauma team service

Who cannot take part

  • Enrolled in another interventional drug study
  • Any active, witnessed, or unable to rule out seizure prior to prophylaxis initiation
  • Received antiseizure medication (ASM), for prophylaxis or treatment, prior to randomization
  • On anti-epileptic medications for seizures or indications other than seizures prior to admission
  • Patient with a GCS of 15 or Legally Authorize Representative (LAR) unable to provide informed consent prior to randomization, or unable to read and understand English, Spanish, Vietnamese, Russian, Arabic, or French
  • History of seizures
  • Documented history of alcohol withdrawal and experiencing alcohol withdrawal on admission with initiation of clinical institute withdrawal assessment scale revised (CIWA-Ar) or modified Minnesota Detoxification Scale (mMINDS) requiring treatment
  • History of bradycardia or permanent pacemaker or signs of bradycardia with HR < 55 bpm for > 5 min not on medications that cause bradycardia
  • End-stage renal disease (ESRD)
  • Spinal cord injury (SCI), confirmed by radiographic imaging demonstrating cervical (C1 to C8) or thoracic-spine (T1 to T12) injuries consistent with spinal cord injury
  • Death, withdrawal of life support or transfer to hospice within 24 hours
  • Pregnant or incarcerated
  • Baseline GCS < 13 or unable to determine baseline GCS

Where in United States

  • Wake Forest University Health SciencesWinston-Salem, United StatesContact: Bailey Baswell, BSTaking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the incidence of early post-traumatic seizures. The study will also assess the benefit of lacosamide compared to levetiracetam in regards to agitation and behavioral adverse effects in patients with traumatic brain injury requiring seizure prophylaxis.

The 2 groups in the trial

  • levetiracetamTreatment being tested

    levetiracetam 1000 mg intravenously or by mouth twice daily for a total of 7 days

  • lacosamideTreatment being tested

    lacosamide 200 mg intravenously or by mouth twice daily for a total of 7 days

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Seizure Prevention in Traumatic Brain Injury: A Comparative Effectiveness Study of Levetiracetam and Lacosamide
Record updated
24 April 2026